Latest from The Angeles Clinic

Morganna Freeman, DO, associate director, Melanoma and Cutaneous Oncology Program, The Angeles Clinic and Research Institute, discusses the challenges associated with treatment selection in melanoma.
Omid A. Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses how to accurately select patients who are likely to have durable and long responses with single-agent immunotherapy versus combination treatment.
Omid Hamid, MD, Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic, discusses a recent trial investigating the combination of vemurafenib and atezolizumab in melanoma in patients with previously untreated BRAF-positive unresectable or metastatic melanoma.
Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses the possibility of using biomarkers to select immunotherapy as a treatment option for patients with melanoma.
Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses the treatment of melanoma.
Omid Hamid, MD, discusses using immune therapy to treat patients with melanoma.
Publication Bottom Border
Border Publication
x